GlassScriptPhysician profile
Drew Soda
NPI 1679233142
$220,305.83
in general payments reported to CMS, 2019-2025
38 companies · $124K in 2025
The $124K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $14K · 2023: $21K · 2024: $61K · 2025: $124K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $148K · Food and Beverage: $20K · Consulting Fee: $16K · Honoraria: $12K · Travel and Lodging: $9,488 · Education: $476.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $148,308.25 |
| Food and Beverage | $19,542.26 |
| Consulting Fee | $16,384.09 |
| Honoraria | $12,405.87 |
| Travel and Lodging | $9,487.79 |
| Education | $475.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $47,476.17 | 2022-2025 | Adbry, Anzupgo |
| Lilly USA, LLC | $41,211.95 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $35,242.17 | 2022-2025 | |
| Incyte Corporation | $22,588.88 | 2022-2025 | Opzelura, Opzelura |
| Botanix Sb INC | $21,482.37 | 2025 | Sofdra |
| Galderma Laboratories, L.P. | $19,536.63 | 2022-2025 | Nemluvio, Aklief, Epsolay |
| Organon LLC | $14,108.44 | 2024-2025 | Vtama |
| Janssen Biotech, INC. | $5,193.84 | 2023-2025 | Tremfya |
| Ucb, INC. | $4,295.53 | 2022-2025 | Bimzelx, Cimzia |
| Sun Pharmaceutical Industries INC. | $1,597.25 | 2022-2025 | Ilumya, Winlevi, Absorica Ld |
| Regeneron Healthcare Solutions, INC. | $1,201.59 | 2022-2025 | Dupixent, Libtayo |
| E.R. Squibb & Sons, L.L.C. | $926.36 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $620.47 | 2022-2024 | Vtama |
| Genzyme Corporation | $580.95 | 2022-2025 | |
| Arcutis Biotherapeutics, INC. | $557.23 | 2023-2025 | Zoryve |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Drew Soda listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.